Aviva Holdings Ltd. Mirati Therapeutics, Inc. Transaction History

Aviva Holdings Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $19.2 Million - $32 Million	275,000 Added 9.61%	3,135,966 $241 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $19.5 Million - $35.4 Million	-275,000 Reduced 8.77%	2,860,966 $369 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $3.23 Million - $4.85 Million	255,264 Added 8.86%	3,135,966 $57.2 Million
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $13.5 Million - $33.7 Million	2,879,702 Added 287970.19%	2,880,702 $0
Q1 2017 Feb 14, 2018	BUY	N/A	1,000	1,000 $5,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Aviva Holdings Ltd., based on Form 13F filings with the SEC.

Stay updated on Aviva Holdings Ltd. with notifications on news.